Estrella Immunopharma Inc. reports a Return on Equity (ROE) of 251.43%.

What is ESLAW's dividend yield?

Estrella Immunopharma Inc. offers a dividend yield of 0.00%.

What is ESLAW's Quality Score?

Our AI rates ESLAW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ESLAW?

Our AI Timing Score for ESLAW is 2 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ESLAW belong to?

Estrella Immunopharma Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Estrella Immunopharma Inc. (ESLAW) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

ESLAW AI Analysis Summary

Our AI summary for ESLAW: Estrella Immunopharma Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 251.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 2/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ESLAW

Estrella Immunopharma Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 0.07

0.01 (9.24%) Day Change

Watchlist Portfolio Compare Chart

-1.69

D/E

251.4%

ROE

-362.3%

ROA

0.00%

Div Yield

ESTRELLA IMMUNOPHARMA INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.07 Price 0.01 (9.24%) Day Change	NEWS SCORE: 87

ESLAW, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

No price data to display chart for the last 3-months of this stock

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.07
PBV / Sector	N/A / 44,105.10
Earning Per Share	N/A

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	553.228110000000
Average 1W Daily Value	124.307880000000

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-362.33 / 185,260.64
ROA Average (%) / Sector	-245.87 / 36,684.64
ROA Change Average (%) / Sector	412.86 / 422,221.42 GREAT
ROE (%) / Sector	251.43 / 243,761.81 GREAT
ROE Average (%) / Sector	-1,192.68 / 48,758.38
ROE Change Average (%) / Sector	1,152.45 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:57
Symbol	ESLAW
Name	ESTRELLA IMMUNOPHARMA INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	0.00
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	N/A / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 5858 Horton Street, EmeryVille, CA, United States, 94608

Phone: 510 318 9098

Website: https://www.estrellabio.com

Sector: Healthcare >> Biotechnology

Description: Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.